COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,042 Articles (22,627 medRxiv, 8,415 bioRxiv)

Most recent first Previous |  Page 119: Articles 1181-1190  | Next

DEVELOPING NEW DUAL-ACTION ANTIVIRAL/ANTI-INFLAMMATORY SMALL MOLECULES FOR COVID-19 TREATMENT USING IN SILICO AND IN-VITRO APPROACHES
Ivanov, V. V., Zakharov, A. B., Anokhin, D. O., Mykhailenko, O. O., Kovalenko, S. M., Yevsieieva, L. V., Georgiyants, V. A., Korinek, M., Chen, Y.-L., Fang, S.-Y., El-Shazly, M., Hwang, T.-L., Kalugin, O. M.
10.1101/2024.11.06.24316825 — Posted: 2024-11-11
Long-term serum spike protein persistence but no correlation with post-COVID syndrome
Fehrer, A., Sotzny, F., Hoheisel, F., Stein, E., Kim, L., Kedor, C., Freitag, H., Heindrich, C., Bauer, S., Rust, R., Seifert, M., Grabowski, P., Babel, N., Scheibenbogen, C., Wittke, K.
10.1101/2024.11.11.24317084 — Posted: 2024-11-11
Modelling complete dynamics of SARS-CoV-2 pandemics of Germany and its federal states using multiple levels of data
Kheifetz, Y., Kirsten, H., Schuppert, A., Scholz, M.
10.1101/2024.11.11.24317088 — Posted: 2024-11-11
Distinct Binding Modes of Inter-Spike Cross-Linking Suggest a Supplementary Mechanism for SARS-CoV-2 Antibody Neutralization
Nan, X., Li, Y., Zhang, R., Wang, R., LV, N., Li, J., Chen, Y., Zhou, B., Wang, Y., Wang, Z., Zhu, J., Chen, J., Li, J., Chen, W., Zhang, Q., Shi, X., Zhao, C., Chen, C., Liu, Z., Zhao, Y., Liu, D., wang, x., Yan, L., Li, T., Zhang, L., Yang, Y. R.
10.1101/2024.11.07.622402 — Posted: 2024-11-11
Comparative Evaluation of Behavioral-Epidemic Models Using COVID-19 Data
Gozzi, N., Perra, N., Vespignani, A.
10.1101/2024.11.08.24316998 — Posted: 2024-11-10
Differential Impacts of the COVID-19 Pandemic on Sociodemographic Groups in England: A Mathematical Model Framework
Oyedele, G. J., Vlaev, I., Tildesley, M. J.
10.1101/2024.11.09.24317003 — Posted: 2024-11-10
Neutralizing Activity and Viral Escape of Pemivibart by SARS-CoV-2 JN.1 sublineages
Yao, T., Ma, Z., Lan, K., Guo, Y., Liu, L.
10.1101/2024.11.08.622746 — Posted: 2024-11-10
Generation of a biosafety mouse model infection for SARS-CoV-2 replicon delivery particles
Li, Y., Huang, X., Deng, J., Tan, X., Liu, Q., Zhou, L., Chen, Y.
10.1101/2024.11.10.622838 — Posted: 2024-11-10
Factors associated with lower COVID-19 vaccine uptake among populations with a migration background in the Netherlands
Smagge, B., Labuschagne, L., Pijpers, J., van Roon, A., van den Hof, S., Hahne, S., de Melker, H.
10.1101/2024.11.07.24316886 — Posted: 2024-11-08
Assessment of Vaccine managers' Knowledge and Observance of Vaccination Norms and Standards in an Urban Health District of Yaounde (Cameroon) during the COVID-19 Pandemic
Lekeumo Cheuyem, F. Z., Amani, A., Ajong, B. N., Otsali, R. K. N., Nouko, A., Guissama, E. O., Ngos, C. S., Mohamadou, A., Nloga, G. S., Edzamba, M. F., Bitye Bi Mvondo, E. A., Ntsek, L. L., Mouangue, C., Kissougle Nkongo, F.
10.1101/2024.11.07.24316922 — Posted: 2024-11-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).